Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 10/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002272 | 0.88 | PDK4 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL7987553 | 0.87 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL6662189 | 0.87 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL7987528 | 0.87 | NR1H2 (0.41) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL597913 | 0.86 | PDK4 (0.45) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL30570071 | 0.86 | PDK4 (0.46) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL12566963 | 0.85 | PDK4 (0.48) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL7677696 | 0.85 | PDK4 (0.44) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL2003552 | 0.84 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 | |
| SCHEMBL2349369 | 0.84 | PDK4 (0.47) | PDK4GRM5GRM1NAMPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022204150-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | BLUE OAK PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-7504432-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20070129397-A1 | Ester derivatives | MSD K.K. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7192969-B2 | Ester derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065211-A1 | Ester derivatives | MSD K.K. (JP) | 2005-03-24 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| EP-1302458-A1 | ESTER DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
| CN-1223659-A | Fused imidazopyridine derivatives as antihyperlipidemic agents | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | PDK4 2078/4885GRM5 608/4885GRM1 455/4885 |
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | PDK4 691/4885GRM5 1883/4885GRM1 1472/4885 |
| US-20070129397-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | PDK4 2978/4885GRM5 719/4885GRM1 195/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | PDK4 3928/4885GRM5 433/4885GRM1 134/4885 |
| US-20050065211-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | PDK4 2984/4885GRM5 735/4885GRM1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.